论文部分内容阅读
目的:探讨布地奈德福莫特罗干粉吸入剂联合督导方法治疗支气管哮喘的临床效果。方法:选取2012年11月至2015年11月期间来江阴医院进行治疗的138例支气管哮喘患者,随机分成观察组与对照组,对照组采用布地奈德福莫特罗干粉吸入剂,观察组采用布地奈德福莫特罗干粉吸入剂和督导方法,比较两组患者的临床效果。结果:两组患者治疗前和治疗后9周的哮喘基本控制率相比较,两组支气管哮喘患者治疗后3周和6周的哮喘基本控制率相比较,两组间的差异具有统计学意义;两组患者治疗3个月后的肺活量(FEV1)和气高峰流量(PEF)与治疗前相比较,两组患者治疗3个月后的FEV1和PEF与对照组相比较,组间的差异均具有统计学意义;观察组患者治疗后不良反应发生率(11.5%)明显低于对照组(14.4%),两组间的差异无统计意义。结论:布地奈德福莫特罗干粉吸入剂联合督导方法可以明显改善患者的支气管哮喘临床症状、肺功能以及患者的生活质量,具有较好的安全性。
Objective: To investigate the clinical efficacy of budesonide formoterol dry powder inhaler combined with supervising method in the treatment of bronchial asthma. Methods: A total of 138 patients with bronchial asthma who were treated in Jiangyin Hospital from November 2012 to November 2015 were randomly divided into observation group and control group. In the control group, inhaled powder of budesonide formoterol was used in the control group, Budesonide Formoterol powder inhaler and supervision method, the clinical effect of two groups of patients were compared. Results: Compared with the basic control rate of asthma in two groups before treatment and 9 weeks after treatment, the basic control rate of asthma in the two groups of bronchial asthma patients at 3 weeks and 6 weeks after treatment was statistically significant. The FEV1 and PEF after 3 months of treatment in both groups were statistically different from those before treatment when compared with those before treatment in both groups after 3 months of treatment The incidence of adverse reactions in the observation group was significantly lower than that in the control group (11.5%) after treatment (14.4%). There was no significant difference between the two groups. Conclusion: The combination of budesonide formoterol powder inhaler and supervision method can improve the clinical symptoms, lung function and quality of life of patients with bronchial asthma significantly and has good safety.